Literature DB >> 3262821

The biological activity and immunotherapeutic properties of AS-101, a synthetic organotellurium compound.

B Sredni1, R R Caspi, S Lustig, A Klein, Y Kalechman, Y Danziger, M Ben Ya'akov, T Tamari, F Shalit, M Albeck.   

Abstract

AS-101 (ammonium trichloro[dioxoethylene-O,O'-]tellurate) is a newly developed synthetic compound with immunomodulating properties and minimal toxicity. We evaluated the effects of AS-101 on various parameters of the activation and function of immunocompetent cells. AS-101 induced IL-2 receptor expression, IL-2 production and proliferation by human and mouse lymphocytes in vitro and enhanced the production colony-stimulating factor (CSF) by mouse spleen cells. In vivo treatment of Balb/c mice with AS-101 caused a significantly increased production of IL-2 and CSF in vitro in the presence of mitogen. When administered systemically to mice, AS-101 mediated antitumor effects in vivo. These results suggest that AS-101 is an active biological response modifier, which might have potential use in the treatment of conditions such as malignancy, AIDS and some types of immune deficiency.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262821

Source DB:  PubMed          Journal:  Nat Immun Cell Growth Regul        ISSN: 0254-7600


  4 in total

1.  Toxicity study in rats of a tellurium based immunomodulating drug, AS-101: a potential drug for AIDS and cancer patients.

Authors:  A Nyska; T Waner; M Pirak; M Albeck; B Sredni
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

2.  The effect of the immunomodulator agent AS101 on interleukin-2 production in systemic lupus erythematosus (SLE) induced in mice by a pathogenic anti-DNA antibody.

Authors:  M Blank; B Sredni; M Albeck; E Mozes; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

3.  Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin.

Authors:  B Sredni; Y Kalechman; M Albeck; O Gross; D Aurbach; P Sharon; S N Sehgal; M J Gurwith; H Michlin
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

4.  Effect of the new immunoregulator AS-101 on in vitro functions of mononuclear cells from patients with systemic lupus erythematosus.

Authors:  J Alcocer-Varela; D Alarcon-Segovia; B Sredni; M Albeck
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.